Navigation Links
QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
Date:11/16/2009

BEDMINSTER, N.J. and SYDNEY, Australia, Nov. 16 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) has today announced the completion of an underwritten institutional placement raising A$8.0 million which was significantly oversubscribed. The Company has also launched a fully underwritten 1 for 5 renounceable rights issue to raise a further A$13.6 million. The combined Placement and Rights Issue will raise A$21.6 million.

The issue price under the Placement and Rights Issue is A$0.80 per share; a 33.3% discount to the last closing price of QRxPharma shares on 10 November 2009.

The Placement and Rights Issue are fully underwritten by RBS Morgans Corporate Limited.

QRxPharma intends to use the proceeds from the Placement and Rights Issue for funding the Phase 3 drug development and expenditure program for its MoxDuo(TM) IR (immediate release dual opioid) product. This includes the lodgment of a New Drug Application with the US Food and Drug Administration in 2010, and for additional working capital purposes.

QRxPharma plans for launch of MoxDuo(TM) IR in the U.S. marketplace in 2011. MoxDuo(TM) IR is intended for the management of moderate to severe acute pain. QRxPharma's product pipeline also includes intravenous (IV) and controlled release (CR) formulations which are in earlier stages of clinical development.

QRxPharma CEO and Managing Director, Dr John Holaday commented, "It is pleasing to see the support we have received from the market for our capital raising. We welcome many new institutional shareholders to our register and look forward to them sharing our success as we progress towards the commercialization of our lead compound MoxDuo(TM) IR. We are encouraged by this strong level of support for the commercialization of MoxDuo(TM)."

Dr. Peter Farrell, Chairman of QRxPharma, stated, "This offering enables the Company to complete the MoxDuo(TM) IR pivotal Phase
'/>"/>

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
7. New Bisphenol A Study Has Limited Capability to Assess Human Health Effects
8. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
9. New Bisphenol A Study Is of Very Limited Relevance to Human Health
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... Israel , July 21, 2014 Galmed ... clinical-stage biopharmaceutical company focused on the development and commercialization ... liver diseases and cholesterol gallstones, announced today that it ... July 25, 2014 to discuss results for the period ... on current developments with respect to its clinical program ...
(Date:7/21/2014)... 2014   Aventura , the leader for ... today that MemorialCare Health System , a ... solution at the Orange Coast Memorial Medical ... Orange Coast Memorial is a 218-bed general ... patients annually. The Aventura Roaming Aware Desktop (RAD) ...
(Date:7/21/2014)... 21, 2014  A new Journal of the ... and scheduled to appear in the August 13 print ... new Hepatitis C Virus (HCV) treatments such as Sovaldi ... CVS Caremark (NYSE: CVS ) Chief Medical ... William Shrank , M.D., suggest that the discussion ...
Breaking Medicine Technology:Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 3MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 4CVS Caremark JAMA Commentary: New Hepatitis C Treatments Highlight Need to Control Costs of High-Priced Specialty Medications 2CVS Caremark JAMA Commentary: New Hepatitis C Treatments Highlight Need to Control Costs of High-Priced Specialty Medications 3
(Date:7/22/2014)... With over 170,000 students now playing high school ... during practice and competition, according to a new study ... Center for Injury Research and Policy at Nationwide Children,s ... today by The American Journal of Sports Medicine ... injuries over the four academic years from 2008 through ...
(Date:7/22/2014)... 2014 Garland’s new Energizer BK ... be used as a flood coat over new and ... a premium restoration material. It provides natural resistance to ... and reducing life-cycle costs. Energizer BK is specially formulated ... water resistance in addition to superior strength and flexibility. ...
(Date:7/22/2014)... CareTouch Communications, Inc. has formed a new ... . CareTouch employees will select causes they are passionate ... line with their mission to help people in and ... cause is Hike for Hospice, to benefit the Butterfly ... 14, the CareTouch in the Community team will climb ...
(Date:7/22/2014)... 2014 Most people encounter the same two problems ... and the second is a fast metabolism. These are hard problems ... provides ways to help fight these problems and to finally gain ... people out there who just can’t seem to eat more than ... are full. The cause of this problem can vary. For some ...
(Date:7/22/2014)... 22, 2014 A new and technologically ... laxity with results that are surprising even the most ... the skin with radio frequency, ThermiTight has been dubbed ... under the skin to “inject” heat to the tissues ... this single treatment solution for skin laxity produces results ...
Breaking Medicine News(10 mins):Health News:High school lacrosse players at risk of concussions other injuries 2Health News:High school lacrosse players at risk of concussions other injuries 3Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:CareTouch is a Peak Sponsor for the 9th Annual Hike for Hospice in Morrison, Colorado 2Health News:CB-1 Weight Gainer Provides Two Tips to Help Customers Gain Weight 2Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2
... report by the public services watchdog, the hospitals in Scotland ... with potentially// fatal condition known as ‘Deep vein thrombosis’ (DVT), ... the leg. ,An enquiry that was conducted in ... DVT, found that the failure to diagnose the condition had ...
... other form of treatment. But to a benefit of all GPs ... ,A resident artist much like resident doctors has been ... Susan Grant, a graduate of the Edinburgh School of Art. ... Council. ,It is one of 27 projects across Scotland ...
... It’s all wired at birth. Even the sex drive, researchers say. ... work to cure 'sex addicts'// , for the answer lies in ... more driven than others in seeking carnal pleasures. ,We ... University of the Negev in Israel. ,The scientists say ...
... bird flu in humans, a senior doctor in Moscow has ... but avian influenza in birds has claimed around 1.1 million ... have started tests on 120 volunteers," said Vitaly Zverev, the ... are mainly medical staff, doctors and donors. They are all ...
... plan to expand joint research into oral and throat ... ,The cooperation between Singapore's National Cancer Centre (NCC) and ... programme credited with cutting the death rate from mouth ... percent. ,The new joint effort, signed Monday, ...
... was found that people who were in their sixties have ... in an increase in the rates of cosmetic surgery. The ... among the procedures used in these surgeries. Statistics show ... of men and women in their sixties having cosmetic surgery ...
Cached Medicine News:Health News:Hospitals In Scotland Not Diagnosing DVT Properly 2
An intermediate set providing a greater range of telescopes than the starter set....
Significantly more compact and tidier in overall looks yet retain many of the excellent features of the more comprehensive Haag type systems., ,Filters include Cobalt blue; green (red free); neut...
... up to 20 tilting ... in the vertical, horizontal ... the option to offset ... transillumination., ,Filters include Cobalt ...
With a high lens and filter range this ophthalmoscope is ideal for the Primary Care Specialist...
Medicine Products: